Phaxiam Therapeutics effects delisting of ADSs from Nasdaq

Phaxiam Therapeutics announced that the company’s voluntary delisting of American Depositary Shares, or ADSs, representing its ordinary shares from Nasdaq has become effective. Each ADS represents one ordinary share of the company. The company will file a Form 15 with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, in respect of the ADSs and the ordinary shares. The company expects that the deregistration of the ADSs under the Exchange Act will become effective 90 days after the filing of the Form 15.